{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:17:18Z","timestamp":1758046638043,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pharma.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T11:17:53Z","timestamp":1587467873000},"page":"426-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00c9ducation th\u00e9rapeutique en r\u00e9adaptation cardiaque\u00a0: impact d\u2019un atelier pluridisciplinaire \u00ab\u00a0M\u00e9dicaments\u00a0\u00bb sur les connaissances des patients \u00e0 court et long terme"],"prefix":"10.1016","volume":"78","author":[{"given":"L.","family":"Laloi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-S.","family":"Leromain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Jarre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hellot-Guersing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Derharoutunian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gadot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6\u20137","key":"10.1016\/j.pharma.2020.03.005_bib0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.acvd.2017.05.001","article-title":"French Registry on Acute ST-elevation and non-ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data","volume":"110","author":"Belle","year":"2017","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.pharma.2020.03.005_bib0145","first-page":"697","article-title":"Recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise de cardiologie concernant la prise en charge de l\u2019infarctus du myocarde apr\u00e8s la phase aigu\u00eb","volume":"94","author":"Delahaye","year":"2001","journal-title":"Arch Mal C\u0153ur Vaiss"},{"issue":"4","key":"10.1016\/j.pharma.2020.03.005_bib0150","first-page":"1","article-title":"\u00c9pid\u00e9miologie et d\u00e9finition de l\u2019infarctus du myocarde","volume":"9","author":"Philippe","year":"2014","journal-title":"EMC Cardiol"},{"issue":"25","key":"10.1016\/j.pharma.2020.03.005_bib0155","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1161\/01.CIR.102.25.3137","article-title":"Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention","volume":"102","author":"Cooper","year":"2000","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.pharma.2020.03.005_bib0160","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pharma.2020.03.005_bib0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.105.505636","article-title":"Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease","volume":"113","author":"Newby","year":"2006","journal-title":"Circulation"},{"issue":"6\u20137","key":"10.1016\/j.pharma.2020.03.005_bib0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.acvd.2010.05.003","article-title":"Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization","volume":"103","author":"Tuppin","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"year":"2012","author":"Ameli (Assurance maladie)","series-title":"Am\u00e9liorer le traitement post infarctus du myocarde","key":"10.1016\/j.pharma.2020.03.005_bib0175"},{"issue":"9667","key":"10.1016\/j.pharma.2020.03.005_bib0180","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharma.2020.03.005_bib0185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00008483-200401000-00008","article-title":"Specific profile and referral bias of rehabilitated patients after an acute coronary syndrome","volume":"24","author":"Cottin","year":"2004","journal-title":"J Cardiopulm Rehabil Prev"},{"unstructured":"France. Code de la sant\u00e9 publique. Article L5125-1-1 A Cr\u00e9\u00e9 par Loi n\u00b0 2009-879 du 21 juillet 2009. JORF n\u00b00167 du 22 juillet 2009, p. 12184.","key":"10.1016\/j.pharma.2020.03.005_bib0190"},{"year":"1998","author":"Organisation mondial de la sant\u00e9 (OMS)","series-title":"Continuing Education Programmes for health care providers in the field of chronic disease","key":"10.1016\/j.pharma.2020.03.005_bib0195"},{"issue":"3","key":"10.1016\/j.pharma.2020.03.005_bib0200","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ancard.2013.04.004","article-title":"Assessment of educational benefits in 73\u00a0hypertensive patients by telephone survey at distance of HTA vasc educational program","volume":"62","author":"Mounier-V\u00e9hier","year":"2013","journal-title":"Ann Cardiol Angeiol"},{"issue":"4","key":"10.1016\/j.pharma.2020.03.005_bib0205","first-page":"299","article-title":"\u00c9ducation th\u00e9rapeutique du patient dans les pathologies cardiovasculaires","volume":"4","author":"Labrun\u00e9e","year":"2012","journal-title":"Arch Cardiovasc Dis Suppl"},{"issue":"5","key":"10.1016\/j.pharma.2020.03.005_bib0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ancard.2011.08.004","article-title":"The coronary patient six months after cardiac rehabilitation: rehabilitation evaluation research (RER study)","volume":"60","author":"Pavy","year":"2011","journal-title":"Ann Cardiol Angeiol"},{"issue":"9","key":"10.1016\/j.pharma.2020.03.005_bib0215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7326\/0003-4819-143-9-200511010-00010","article-title":"Meta-analysis: secondary prevention programs for patients with coronary artery disease","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1016\/j.pharma.2020.03.005_bib0220","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1001\/archinte.168.20.2194","article-title":"Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network","volume":"168","author":"Giannuzzi","year":"2008","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.pharma.2020.03.005_bib0225","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.rehab.2012.04.003","article-title":"Therapeutic education in cardiovascular diseases: state of the art and perspectives","volume":"55","author":"Labrun\u00e9e","year":"2012","journal-title":"Ann Phys Rehabil Med"},{"issue":"4","key":"10.1016\/j.pharma.2020.03.005_bib0230","first-page":"810","article-title":"Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials","volume":"44","author":"McAlister","year":"2004","journal-title":"J Am Coll Cardiol"},{"year":"2014","author":"Haute Autorit\u00e9 de sant\u00e9 (HAS)","series-title":"Les \u00e9valuations d\u2019un programme d\u2019\u00e9ducation th\u00e9rapeutique patient (ETP)","key":"10.1016\/j.pharma.2020.03.005_bib0235"},{"issue":"16","key":"10.1016\/j.pharma.2020.03.005_bib0240","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/archinte.159.16.1939","article-title":"Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) Study","volume":"159","author":"Gattis","year":"1999","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.pharma.2020.03.005_bib0245","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/archinte.168.7.687","article-title":"Pharmacist care of patients with heart failure: a systematic review of randomized trials","volume":"168","author":"Koshman","year":"2008","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.pharma.2020.03.005_bib0250","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.revmed.2015.04.009","article-title":"Intervention des patients dans l\u2019animation d\u2019un programme d\u2019\u00e9ducation th\u00e9rapeutique d\u00e9di\u00e9 au lupus syst\u00e9mique\u00a0: d\u00e9finitions, mise en place et b\u00e9n\u00e9fices","volume":"36","author":"Hervier","year":"2015","journal-title":"Rev Med Interne"},{"issue":"7606","key":"10.1016\/j.pharma.2020.03.005_bib0255","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.39227.698785.47","article-title":"How effective are expert patient (lay led) education programmes for chronic disease?","volume":"334","author":"Griffiths","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pharma.2020.03.005_bib0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.HCR.0000265015.44210.bf","article-title":"Outcomes at one-year follow-up of women and men with coronary artery disease discharged from cardiac rehabilitation: what benefits are maintained?","volume":"27","author":"Gupta","year":"2007","journal-title":"J Cardiopulm Rehabil Prev"},{"issue":"3","key":"10.1016\/j.pharma.2020.03.005_bib0265","first-page":"306","article-title":"Comparative outcome one year after formal cardiac rehabilitation: the effects of a randomized intervention to improve exercise adherence","volume":"15","author":"Arrigo","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol"},{"issue":"4","key":"10.1016\/j.pharma.2020.03.005_bib0135","first-page":"203","article-title":"Nurse-led telephone interventions for people with cardiac disease: a review of the research literature","volume":"9","author":"Stolic","year":"2010","journal-title":"Eur J Cardiovasc Nurs J Work Group Cardiovasc Nurs Eur Soc Cardiol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450920300316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:34:21Z","timestamp":1757720061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450920300316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0003450920300316"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2020.03.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9ducation th\u00e9rapeutique en r\u00e9adaptation cardiaque\u00a0: impact d\u2019un atelier pluridisciplinaire \u00ab\u00a0M\u00e9dicaments\u00a0\u00bb sur les connaissances des patients \u00e0 court et long terme","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}